CSBR 最新10-K变化

相对上期删除的文字 · 来源:10-K · 2025-07-23

• of operations, there can be no assurances that further unforeseen events will not have a material adverse effect on us or our operations in the future.

相对上期新增的文字 · 来源:10-K · 2026-07-27

• •Pharmacology services revenue increased for the year ended April 30, 2026 compared to the prior year. The increase was primarily driven by improved conversion of previously booked studies into revenue, including studies that had been expected to convert in the prior fiscal year but were delayed int…

• •TOS data license revenue decreased for the year ended April 30, 2026 compared to the prior year. Fiscal 2025 revenue primarily reflected a significant data license transaction with a single customer, while fiscal 2026 revenue was generated from multiple, smaller customer contracts. Although fiscal …

• •Other TOS revenue includes additional clinical services provided to the Company's pharmaceutical and biotechnology customers specifically for flow cytometry and SaaS provided via Lumin. Other TOS revenue decreased for the year ended April 30, 2026 compared to the prior year, primarily due to lower …

• Cost of oncology revenue was $30.9 million and $28.4 million for the years ended April 30, 2026 and 2025, respectively, an increase of $2.5 million or 8.8%. The increase was primarily driven by higher outsourced laboratory costs associated with the expansion of our radiopharmacology services. During…

• Research and development expense was $9.1 million and $6.8 million for the years ended April 30, 2026 and 2025, respectively, an increase of $2.3 million or 33.1%.

相对上期删除的文字 · 来源:10-K · 2025-07-23

• biomarker hypotheses, reveal potential mechanisms of therapeutic resistance, and guide the direction of additional preclinical evaluations.

• •The increase for the year ending April 30, 2025 was the result of a stronger bookings to revenue conversion rate. Bookings, which represent the total value of signed statements of work, convert to revenue over time as the Company fulfills its contractual performance obligations. Operational improve…

• •Revenue for the year ending April 30, 2025 resulted from the sale of data licenses. No such revenues occurred for the year ending April 30, 2024.

• •Other TOS Revenue includes additional clinical services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry and SaaS provided via Lumin.

• •Our flow cytometry services revenue increased approximately $787,000 for the year ending April 30, 2025 due to stronger bookings to revenue conversion rates.